Valneva SE Lifts Restrictions on Chikungunya Vaccine IXCHIQ
Valneva SE, a specialized vaccine firm, has exciting news regarding its chikungunya vaccine, IXCHIQ. The European Medicines Agency has officially lifted the temporary restrictions on the use of this vaccine for individuals aged 65 and older. This decision follows a comprehensive review conducted by the agency's safety committee, ensuring the vaccine's benefits outweigh any potential risks.
Understanding the Safety Review and Its Outcome
The safety committee's assessment, which began earlier this year, focused on addressing concerns about serious side effects experienced primarily by older adults with existing medical issues. Importantly, the EMA emphasized that while there are contraindications for those with weakened immune systems, IXCHIQ can still offer significant protection when the threat of chikungunya is high.
The EMA's review highlighted the efficacy of IXCHIQ in provoking an immune response among seniors, a demographic particularly vulnerable to severe chikungunya illness. Hence, the vaccine is considered a valuable option for those who might be exposed to the virus.
About Chikungunya and its Global Impact
Chikungunya, caused by the chikungunya virus (CHIKV) and transmitted by infected mosquitoes, presents significant health risks. The symptoms include fever, debilitating joint pain, and various other ailments that can linger for weeks or even years. The global emergence of chikungunya began around 2004, leading to outbreaks across numerous continents, with cases documented in over 110 countries.
In the Americas alone, more than 3.7 million cases were reported between 2013 and 2023. The economic consequences of this disease are profound, particularly as changing climates may allow the mosquitoes that spread chikungunya to expand their reach further. The World Health Organization has underscored chikungunya as a significant public health issue that necessitates ongoing focus.
The Role of Valneva SE in Vaccine Development
Valneva SE operates with the mission of developing and commercializing vaccines to combat infectious diseases. Their commitment to addressing unmet healthcare needs is evident in their development strategy, which integrates advanced research and diligent safety reviews, ensuring that their vaccines are both effective and safe.
Valneva has a commendable history, having successfully navigated multiple vaccines from early research stages to market. Their portfolio includes three proprietary travel vaccines, and they continue to advance their vaccine pipeline. This pipeline features the only Lyme disease vaccine currently in advanced trials, in partnership with Pfizer, as well as candidates for other diseases posing global health risks, such as the Zika virus.
Contact Information for Media and Investor Relations
Laetitia Bachelot-Fontaine
VP Global Communications & European Investor Relations
M +33 (0)6 4516 7099
laetitia.bachelot-fontaine@valneva.com
Joshua Drumm, Ph.D.
VP Global Investor Relations
M +001 917 815 4520
joshua.drumm@valneva.com
Frequently Asked Questions
What is IXCHIQ?
IXCHIQ is Valneva's vaccine for the chikungunya virus, designed to provide immunity against this mosquito-borne disease.
Why were there restrictions lifted for seniors?
The European Medicines Agency concluded that the benefits of IXCHIQ outweigh the risks for individuals aged 65 and older.
What are the main symptoms of chikungunya?
Symptoms include fever, severe joint pain, headache, nausea, fatigue, and rash, which can last for weeks or years.
How effective is IXCHIQ for older adults?
IXCHIQ has been shown to be effective in stimulating an immune response, particularly in older adults who are at higher risk for severe disease.
How does climate change affect chikungunya transmission?
As climate change progresses, it could enable the mosquitoes that transmit chikungunya to expand their range, increasing the risk of outbreaks.
